IL6 and breast cancer: Other risk factors for frailty decline following chemotherapy initiation include inflammatory biomarkers, such as interleukin-6 (IL-6) and C-reactive protein (CRP).13 Findings from our study and others suggest that assessing a broad range of aging-related domains may help identify older women with breast cancer who are at the highest risk of decline during adjuvant chemotherapy treatment.